Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study

scientific article

Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/APT.12522
P8608Fatcat IDrelease_5w7dz455lzgm5oipvew6md3wk4
P932PMC publication ID4028985
P698PubMed publication ID24117847
P5875ResearchGate publication ID257751022

P50authorEmmanuel TsochatzisQ28320718
Pinelopi ManousouQ88955142
P2093author name stringA K Burroughs
G Germani
C Rigamonti
S Karatapanis
V Papastergiou
G Pieri
E Thalassinos
M Rodriguez-Peralvarez
V Arvaniti
P2860cites workUrsodeoxycholic acid for primary biliary cirrhosisQ24241945
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study GroupQ28243457
Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseasesQ33723536
Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysisQ33745849
Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohortQ35596580
Hepatology may have problems with putative surrogate outcome measuresQ36742914
Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosisQ37760788
Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic modelQ38937793
Prediction of short-term survival with an application in primary biliary cirrhosisQ39085766
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosisQ40737262
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic AcidQ43483632
Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patientsQ44617739
Ursodeoxycholic acid and histological progression in primary biliary cirrhosisQ44671802
Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach.Q44706114
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosisQ45247238
Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.Q45250878
Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acidQ46126105
Prognosis in primary biliary cirrhosis: model for decision makingQ46316848
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosisQ46408092
Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acidQ46521938
A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosisQ51586165
EASL Clinical Practice Guidelines: management of cholestatic liver diseases.Q55051951
Primary biliary cirrhosisQ56428273
Primary biliary cirrhosisQ72331434
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapyQ77058192
Primary biliary cirrhosisQ81246142
Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcomeQ84441124
American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosisQ84476629
P433issue11-12
P407language of work or nameEnglishQ1860
P921main subjectprimary biliary cholangitisQ1072420
P304page(s)1354-1364
P577publication date2013-10-05
P1433published inAlimentary Pharmacology & TherapeuticsQ4726656
P1476titleBiochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study
P478volume38

Reverse relations

cites work (P2860)
Q91431676Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis
Q55324101Biomarkers for primary biliary cholangitis: current perspectives.
Q38744215Emerging drugs for the treatment of Primary Biliary Cholangitis
Q91844615Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
Q41531249New developments in the treatment of primary biliary cholangitis - role of obeticholic acid
Q38192045Primary biliary cirrhosis in adults
Q58597198Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio
Q26796355Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists
Q46813053The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.

Search more.